ClinicalTrials.gg
TerminatedNCT00739050Updated May 23, 2024Results posted

Effect of Simvastatin on Endothelial Function in Premenopausal Women With Systemic Lupus Erythematosus (0733-271)(TERMINATED)

A Phase 4 interventional study of simvastatin and Comparator: Placebo in Systemic Lupus Erythematosus, sponsored by Organon and Co. Terminated. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-23.

Sponsored by Organon and Co · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 11 months after the study started (first participant enrolled Sep 2007, registered Aug 2008).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
4
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

Women with Systemic Lupus Erythematosus (SLE) are prone to cardiovascular disease. Early detection of improvement of endothelial function with simvastatin could be a clue for future intervention trials.

02

Conditions studied

  • Systemic Lupus Erythematosus
03

In context

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

This study's enrollment of 4 is below the median of 52 across 878 interventional studies indexed under Lupus Erythematosus, Systemic.

Browse Lupus Erythematosus, Systemic studies →

Lead sponsor

Organon and Co is the lead sponsor of 505 studies on the registry; none are open to participants now.

Of its 23 completed or terminated interventional studies of FDA-regulated products, 18 (78%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female Patients Over 18 Years Old
  • Confirmed Systemic Lupus Erythematosus (SLE) diagnosis according to American College of Rheumatology (ACR)
  • Signed Form (ICF)

Exclusion criteria

Exclusion Criteria:

  • Patients With LDL-C Below 90 mg/dL
  • Pregnant Or Breast Feeding
  • Diabetes Mellitus
  • Or Any Organ Disfunction
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
4 participants (actual)

Study arms

  • Experimental
    1

    Arm 1: Drug

    Drug: simvastatin

  • Placebo comparator
    2

    Arm 2: Placebo

    Drug: Comparator: Placebo

Interventions

  • simvastatin 20mg daily at nights for 12 weeks. Tablets

    Also known as: Zocor, MK0733

  • DrugComparator: Placebo

    placebo daily at nights for 12 weeks. Tablets

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Endothelial Thickness After 12 Weeks of Treatment.

    The study was terminated; no outcome measure data analyses were conducted.

    Time frame: Baseline and 12 weeks

Secondary outcomes

  1. Change in Total Cholesterol From Baseline at Week 12

    The study was terminated; no outcome measure data analyses were conducted.

    Time frame: Baseline and 12 weeks

  2. Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) After 12 Weeks of Treatment

    The study was terminated; no outcome measure data analyses were conducted.

    Time frame: Baseline and 12 weeks

  3. Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) After 12 Weeks of Treatment

    The study was terminated; no outcome measure data analyses were conducted.

    Time frame: Baseline and 12 weeks

07

Results

Posted Dec 16, 2010
Limitations and caveats
The Investigator was not able to recruit the required patients and was not able to get the necessary equipment. The protocol was terminated for Administrative Reasons.

Participant flow

First patient enrolled (FPE): 19 Sept 2007; Last patient enrolled (LPE) 22 Oct 2007. The protocol was terminated for Administrative Reasons

Participant flow — Overall Study
MilestoneSimvastatinPlacebo
Started40
Completed30
Not completed10

Outcome measures

PrimaryChange From Baseline in Endothelial Thickness After 12 Weeks of Treatment.

The study was terminated; no outcome measure data analyses were conducted.

Time frame:
Baseline and 12 weeks

No measurements were reported for this outcome.

SecondaryChange in Total Cholesterol From Baseline at Week 12

The study was terminated; no outcome measure data analyses were conducted.

Time frame:
Baseline and 12 weeks

No measurements were reported for this outcome.

SecondaryChange From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) After 12 Weeks of Treatment

The study was terminated; no outcome measure data analyses were conducted.

Time frame:
Baseline and 12 weeks

No measurements were reported for this outcome.

SecondaryChange From Baseline in High Density Lipoprotein Cholesterol (HDL-C) After 12 Weeks of Treatment

The study was terminated; no outcome measure data analyses were conducted.

Time frame:
Baseline and 12 weeks

No measurements were reported for this outcome.

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Simvastatin—0/4 (0%)0/4 (0%)
Placebo———

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)All Participants
<=18 years0
Between 18 and 65 years4
>=65 years0
Sex: Female, Male
Sex: Female, Male(Participants)All Participants
Female4
Male0
Total Cholesterol
Total Cholesterol(mg/dL)All Participants
Mean176.67 ± 28.50
Low Density Lipoprotein Cholesterol (LDL-C)
Low Density Lipoprotein Cholesterol (LDL-C)(mg/dL)All Participants
Mean105 ± 23.64
High Density Lipoprotein Cholesterol (HDL-C)
High Density Lipoprotein Cholesterol (HDL-C)(mg/dL)All Participants
Mean53 ± 10.15
08

Study locations

No study locations are listed for this record.

09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2007 to primary completion in Feb 2008, 4 months.

Results were first posted in Dec 2010, 2 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2008
First posted
Aug 21, 2008
StartActual
Sep 19, 2007
Primary completionActual
Feb 1, 2008
CompletionActual
Feb 1, 2008
Results first posted
Dec 16, 2010
Last update
May 23, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00739050
Lead sponsor
Organon and Co
Responsible party
Sponsor
First posted
Aug 21, 2008
Start date
Sep 19, 2007
Primary completion
Feb 1, 2008
Completion
Feb 1, 2008
Results posted
Dec 16, 2010
Last update
May 23, 2024

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Simvastatin

Start the discussion